SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 5, 2023 / If you suffered a loss on your BioXcel Therapeutics, Inc. (NASDAQ:BTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/bioxcel-lawsuit-submission-form?prid=46562&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against BioXcel Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company lacked adequate internal controls over protocol adherence and data integrity; (2) as a result, the Company's principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) the Company's principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) the Company's principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) the foregoing would negatively impact the Company's ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer's disease; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT'S NEXT? If you suffered a loss in BioXcel stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/bioxcel-lawsuit-submission-form?prid=46562&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP